Industry News
Biotechnology Industry News
A phase 3 rheumatoid arthritis…
A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by existing drugs.
Novartis’ continuing search for…
Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro Pharmaceuticals.
Teva has penned a second pact with…
Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development of a drug for vitiligo.
Eikon Therapeutics is planning to…
Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign that the public markets are looking increasingly attractive to drug developers.
Eli Lilly and Nvidia, two primary…
Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through AI-powered drug development.
The Trump administration spent…
The Trump administration spent 2025 taking a sledgehammer to science, obliterating funding and reshaping agencies like the FDA and the National Institutes of Health through layoffs and restrictive new policies. In a new letter, Noubar
The new year has ushered in a flow…
The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz.
AirNexis Therapeutics is taking…
AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a China pharma that aims to treat lung disease.
Madrigal paid Pfizer $50 million…
Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.
Menlo Ventures has made a $16…
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable.
Roche has got in on the B7-H3…
Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an ADC targeting the immune checkpoint protein.
Aktis Oncology exceeded its own…
Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year.
After netting a $361 million…
After netting a $361 million series C funding round in October, 2024 Fierce 15 winner Tubulis has reeled in a big name for its chief medical officer spot in Charles Fuchs, M.D. Fuchs is a
The life sciences world is once…
The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026. Fierce Biotech is here tracking the biggest deals, data drops and industry shifts as
After unsheathing just a few…
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early-stage study.
As biotech and pharma investment…
As biotech and pharma investment surges nationwide, Ohio is investing $30 million for training the next generation of biomanufacturing talent.
GSK has committed $50 million in…
GSK has committed $50 million in upfront capital and near-term milestones to secure a license to two cancer research foundation models from Noetik.
Tessera Therapeutics is planning…
Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned.
Protein degradation biotech…
Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.
Foresee Pharmaceuticals has sold a…
Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.